Osteosarcoma Journey in India: Each Step Reveals a New Horizon!

Jyoti Bajpai; Arun Chandrashekharan; Shripad D Banavali; Sudeep Gupta

doi:10.4103/ijmpo.ijmpo_15_20

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(01): 4-6
DOI: 10.4103/ijmpo.ijmpo_15_20

Editorial Commentary

Osteosarcoma Journey in India: Each Step Reveals a New Horizon!

Jyoti Bajpai

Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India

Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, Maharashtra, India

,

Arun Chandrashekharan

Department of Medical Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India

,

Shripad D Banavali

Department of Medical and Pediatric Oncology, TMC-Rural Outreach Program, Tata Memorial Centre, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India

,

Sudeep Gupta

Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India

Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, Maharashtra, India

References
1 Bajpai J, Jaffe N. Perspectives of the role of chemotherapy in the management of osteosarcoma. JCT 2012; 03: 1191-203
2 Souhami RL, Craft AW, van der Eijken JW, Nooij M, Spooner D, Bramwell VH. et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911-7
3 Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B. et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen ’OGS-12’. Eur J Cancer 2017; 85: 49-58
4 Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-51
5 Bajpai J, Chandrasekharan A, Simha V, Mandal T, Shah K, Hingmare S. et al. Osteosarcoma journey over two decades in India: Small steps, big changes. Pediatr Blood Cancer 2019; 66: e27877
6 Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17
7 Sukumaran RK, Rajeshwari B, Sugath S, Chellappan SG, Thankamony P, Parukuttyamma K. Methotrexate free chemotherapy and limb salvage surgery for paediatric osteosarcoma in India. Indian J Orthop 2018; 52: 58-64
8 Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA. et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009; 53: 1035-9
9 Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S. et al. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. J Surg Oncol 2015; 112: 662-8
10 Bajpai J, Gamanagatti S, Sharma MC, Kumar R, Vishnubhatla S, Khan SA. et al. Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer 2010; 54: 526-31
11 Hasakova K, Vician M, Reis R, Zeman M, Herichova I. Sex-dependent correlation between survival and expression of genes related to the circadian oscillator in patients with colorectal cancer. Chronobiol Int 2018; 35: 1423-34
12 Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther 1994; 64: 529-64
13 Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother 2001; 50: 391-6
14 Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM. et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP:First results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 2015; 33: 2279-87
15 Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating progress makes for a hopeful future. Front Oncol 2018; 8: 4